STAT3 mRNA Inhibition via Antisense Oligonucleotides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents targeting STAT3 activation in cancers are not direct inhibitors, and the development of STAT3 inhibitors is hindered by the lack of a tyrosine kinase domain and close homology to other STAT signaling pathway members, leading to non-specific inhibition of other STAT isoforms.
Innovation Solution
Design and use of nucleic acids, specifically oligonucleotides and double-stranded nucleic acids, that are at least 80% complementary to STAT3 mRNA sequences to inhibit STAT3 expression, including oligonucleotides targeting the 3'-UTR region and aptamers attached to antisense strands for enhanced specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents (monoclonal antibodies against IL-6 receptor, JAK tyrosine kinase inhibitors) are used to target STAT3 activation, then STAT3 signaling is inhibited, but the inhibition is indirect and not specific to STAT3
Solution Approach 1:
The patent extracts the specific targeting function from indirect inhibitors and applies it directly to STAT3 mRNA through antisense oligonucleotides. The antisense strand is designed to be complementary to specific STAT3 mRNA sequences, enabling direct and specific inhibition of STAT3 expression without affecting other STAT isoforms or requiring indirect pathways through JAK inhibitors or IL-6 receptor antibodies.
Solution Approach 2:
The patent uses a dual-stranded nucleic acid structure where the antisense strand acts as the primary mediator for STAT3 mRNA binding and inhibition, while the sense strand serves as a protective intermediary that forms a double-stranded structure to enhance stability and reduce degradation. This intermediary structure resolves the contradiction by providing both specificity (through antisense targeting) and stability (through double-stranded protection).
2Reliability
If siRNA is used to inhibit STAT3 expression, then STAT3 mRNA is reduced, but off-target effects on other STAT isoforms occur due to sequence homology
Solution Approach 1:
The patent applies local quality by designing the antisense strand to target a specific local region of STAT3 mRNA (sequences disclosed in the patent) that is unique to STAT3 and distinct from other STAT isoforms. This localized targeting ensures high specificity to STAT3 while avoiding off-target effects on STAT1, STAT2, STAT4, STAT5A, STAT5B, and STAT6, resolving the contradiction between efficacy and specificity.
3Stability of the object's composition
If single-stranded oligonucleotides are used to target STAT3 mRNA, then the structure is simple, but stability and resistance to degradation are reduced
Solution Approach 1:
The patent merges the antisense strand (which provides targeting specificity) with the sense strand (which provides structural stability) into a dual-stranded nucleic acid complex. This combination resolves the contradiction by integrating both functions: the antisense strand ensures specific binding to STAT3 mRNA, while the sense strand forms a stable double-stranded structure that protects against nucleases and enhances overall compositional stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach achieves specific knockdown of STAT3 mRNA and protein, reducing colony formation in cancer cell lines with minimal off-target effects on other STAT isoforms, demonstrating enhanced specificity and potency compared to existing siRNAs.
Implementation Method 1
an antisense strand which is at least 80% complementary to a target STAT3 mRNA sequence
Implementation Method 2
an aptamer which is attached to one end of the antisense strand via a linker
Data Source
AI summary
The present invention relates to nucleic acids, double stranded nucleic acids (dsNAs), and agents for inhibiting expression of STATS. The present invention also includes nanoparticles comprising the nucleic acids, the dsNAs, and/or the agents as well as methods of treating cancer using the nucleic acids, the double stranded nucleic acids (dsNAs), the agents and/or the nanoparticles as disclosed herein. In one embodiment, the target region is within the 3′-UTR region of STATS mRNA.